TCGA-49-AARR-01A-11R-A41B-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.410
- COAGULATION+0.380
- KRAS_SIGNALING_DN+0.330
- BILE_ACID_METABOLISM+0.310
- HEDGEHOG_SIGNALING+0.300
- IL6_JAK_STAT3_SIGNALING+0.240
- UV_RESPONSE_DN+0.210
- APICAL_SURFACE+0.200
- INFLAMMATORY_RESPONSE+0.200
- COMPLEMENT+0.180
Top 10 suppressed
- MYC_TARGETS_V1-0.760
- E2F_TARGETS-0.740
- MYC_TARGETS_V2-0.680
- G2M_CHECKPOINT-0.660
- MTORC1_SIGNALING-0.590
- OXIDATIVE_PHOSPHORYLATION-0.590
- UNFOLDED_PROTEIN_RESPONSE-0.540
- PROTEIN_SECRETION-0.510
- DNA_REPAIR-0.480
- GLYCOLYSIS-0.460
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | sclcMAD11162_S44.txt | — | cohortA1 | 0.966 |
| 2 | TCGA-75-7025-01A-12R-1949-07 | — | cohortA1 | 0.939 |
| 3 | TCGA-98-A53H-01A-12R-A262-07 | — | cohortA1 | 0.936 |
| 4 | BS_21RE8W46 | pilocytic astrocytoma | — | 0.918 |
| 5 | TCGA-55-8619-01A-11R-2403-07 | — | cohortA1 | 0.918 |
| 6 | TCGA-99-AA5R-01A-11R-A39D-07 | — | cohortA1 | 0.916 |
| 7 | BS_YZ2Z1Q6Y | pilocytic astrocytoma | — | 0.915 |
| 8 | TCGA-97-A4M5-01A-11R-A24X-07 | — | cohortA1 | 0.915 |
| 9 | SRR6013548 | — | cohortA1 | 0.914 |
| 10 | SRR658645 | GTEX | — | 0.914 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.410 | Inavolisib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.310 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| COMPLEMENT | 0.180 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.140 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| APICAL_JUNCTION | 0.080 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.060 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.010 | Idelalisib | — uncovered |